Forest Laboratories Management Discusses Q3 2013 Results – Earnings Call

Forest Laboratories Management Discusses Q3 2013 Results – Earnings Call
… let me read out the sales for our third quarter for some of our smaller products here: Campral, $ 5.7 million; Celexa, $ 3.9 million; Cervidil, $ 13.7 million; Esgic, $ 0.6 million; European sales, $ 34.4 million; generic sales, $ 7 million; Lexapro, $ 20 …

Full News here – Read more on Seeking Alpha

Leave a Reply